Luye Pharma Chairman Dianbo Liu On Taking “Made In China” Overseas: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Established nearly 20 years ago with $50,000, China’s Luye Pharma now has multiple products in clinical trials in the United States. In a rare interview, Luye Chairman Dianbo Liu shares his views on incremental innovation in China, and bringing traditional Chinese medicines to the world.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.